Saad Usmani to Risk Assessment
This is a "connection" page, showing publications Saad Usmani has written about Risk Assessment.
Connection Strength
0.665
-
Li S, Natwick T, Liu J, Morrison VA, Vidito S, Werther W, Yusuf AA, Usmani SZ. Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States. J Geriatr Oncol. 2019 05; 10(3):490-496.
Score: 0.384
-
Patel JN, Robinson M, Jagosky M, Slaughter D, Arnall J, Jandrisevits E, Matusz-Fisher A, Atrash S, Paul B, Bhutani M, Voorhees P, Usmani SZ. Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):188-198.e2.
Score: 0.109
-
Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 10; 22(10):1893-1899.
Score: 0.081
-
Biran N, Dhakal B, Niesvizky R, Lentzsch S, Bhutani D, McKay JT, Vesole DH, Nooka A, Paul B, Hari PN, D'Ambrosi S, Kuiper R, van Vliet M, Siegel D, Usmani SZ, van Rhee F. Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data. Br J Haematol. 2025 Jun; 206(6):1642-1653.
Score: 0.037
-
Gran C, Luong V, Bruchfeld JB, Liwing J, Afram G, Lund J, Usmani S, Alici E, Nahi H. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. Am J Hematol. 2021 03 01; 96(3):E63-E65.
Score: 0.027
-
Yan X, Xu XS, Weisel KC, Mateos MV, Sonneveld P, Dimopoulos MA, Usmani SZ, Bahlis NJ, Puchalski T, Ukropec J, Bellew K, Ming Q, Sun S, Zhou H. Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. Clin Transl Sci. 2020 11; 13(6):1345-1354.
Score: 0.027